Abstract
The aim of the study was to establish a model of tumour microcirculation in vivo using the murine renal cell carcinoma cell line (RENCA) implanted into the mouse cremaster muscle, and subsequently to investigate the trafficking of syngeneic lymphocyte subpopulations into both the RENCA tumour and the surrounding normal cremaster muscle microcirculation. We have demonstrated that RENCA tumour cells, at a dose of 1.5 x 10(5) per 30 microl injected into the cremaster muscle, reproducibly produced a vascularized tumour suitable for in vivo microscopy at 10-14 days. Injection of fluorescently labelled effector cells (1 x 10(6)) including naive splenocytes, T-cell enriched populations and ex vivo interleukin 2 (IL-2)-activated splenocytes all migrated to and flowed through both the tumour and the normal microcirculation, with negligible adhesion. However, we observed the selective recruitment, localization and arrest of IL-2-activated splenocytes (P < 0.05) into the tumour microcirculation, and the subsequent extravasation of cells into the tumour intestitium in some instances. This did not occur with the other effector cells. We also observed the absence of leucocyte rolling in the tumour microcirculation, suggesting an impairment in adhesion molecule expression on the tumour endothelium. We have therefore established the potential of this model for defining further effector cell-tumour-endothelium interactions.
Full text
PDF






Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baez S. An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy. Microvasc Res. 1973 May;5(3):384–394. doi: 10.1016/0026-2862(73)90054-x. [DOI] [PubMed] [Google Scholar]
- Basse P. H., Nannmark U., Johansson B. R., Herberman R. B., Goldfarb R. H. Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J Natl Cancer Inst. 1991 Jul 3;83(13):944–950. doi: 10.1093/jnci/83.13.944. [DOI] [PubMed] [Google Scholar]
- Basse P., Herberman R. B., Hokland M., Goldfarb R. H. Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels. Cancer Immunol Immunother. 1992;34(4):221–227. doi: 10.1007/BF01741789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Basse P., Hokland P., Hokland M. Comparison between 125IUdR and 51Cr as cell labels in investigations of tumor cell migration. Int J Rad Appl Instrum B. 1990;17(8):781–791. doi: 10.1016/0883-2897(90)90026-w. [DOI] [PubMed] [Google Scholar]
- Bassil B., Dosoretz D. E., Prout G. R., Jr Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol. 1985 Sep;134(3):450–454. doi: 10.1016/s0022-5347(17)47235-1. [DOI] [PubMed] [Google Scholar]
- Bergers J. J., Den Otter W., Dullens H. F., De Groot J. W., Steerenberg P. A., Filius P. M., Crommelin D. J. Effect of immunomodulators on specific tumor immunity induced by liposome-encapsulated tumor-associated antigens. Int J Cancer. 1994 Mar 1;56(5):721–726. doi: 10.1002/ijc.2910560518. [DOI] [PubMed] [Google Scholar]
- Brown N. J., Reed M. W. Leucocyte interactions with the mouse cremaster muscle microcirculation in vivo in response to tumour-conditioned medium. Br J Cancer. 1997;75(7):993–999. doi: 10.1038/bjc.1997.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ettinghausen S. E., Lipford E. H., 3rd, Mulé J. J., Rosenberg S. A. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol. 1985 Nov;135(5):3623–3635. [PubMed] [Google Scholar]
- Ettinghausen S. E., Rosenberg S. A. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res. 1986 Jun;46(6):2784–2792. [PubMed] [Google Scholar]
- Fukumura D., Salehi H. A., Witwer B., Tuma R. F., Melder R. J., Jain R. K. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res. 1995 Nov 1;55(21):4824–4829. [PubMed] [Google Scholar]
- Hayat K., Rodgers S., Bruce L., Rees R. C., Chapman K., Reeder S., Dorreen M. S., Sheridan E., Sreenivasan T., Hancock B. W. Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2. Eur J Cancer. 1991;27(8):1009–1014. doi: 10.1016/0277-5379(91)90270-n. [DOI] [PubMed] [Google Scholar]
- Jain R. K. Determinants of tumor blood flow: a review. Cancer Res. 1988 May 15;48(10):2641–2658. [PubMed] [Google Scholar]
- Lafreniere R., Rosenberg S. A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985 Aug;45(8):3735–3741. [PubMed] [Google Scholar]
- Ley K., Bullard D. C., Arbonés M. L., Bosse R., Vestweber D., Tedder T. F., Beaudet A. L. Sequential contribution of L- and P-selectin to leukocyte rolling in vivo. J Exp Med. 1995 Feb 1;181(2):669–675. doi: 10.1084/jem.181.2.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Melder R. J., Salehi H. A., Jain R. K. Interaction of activated natural killer cells with normal and tumor vessels in cranial windows in mice. Microvasc Res. 1995 Jul;50(1):35–44. doi: 10.1006/mvre.1995.1036. [DOI] [PubMed] [Google Scholar]
- Melder R. J., Walker E. R., Herberman R. B., Whiteside T. L. Surface characteristics, morphology, and ultrastructure of human adherent lymphokine-activated killer cells. J Leukoc Biol. 1990 Aug;48(2):163–173. doi: 10.1002/jlb.48.2.163. [DOI] [PubMed] [Google Scholar]
- Murphy G. P., Hrushesky W. J. A murine renal cell carcinoma. J Natl Cancer Inst. 1973 Apr;50(4):1013–1025. doi: 10.1093/jnci/50.4.1013. [DOI] [PubMed] [Google Scholar]
- Palmer P. A., Vinke J., Evers P., Pourreau C., Oskam R., Roest G., Vlems F., Becker L., Loriaux E., Franks C. R. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur J Cancer. 1992;28A(6-7):1038–1044. doi: 10.1016/0959-8049(92)90450-g. [DOI] [PubMed] [Google Scholar]
- Reed M. W., Wieman T. J., Schuschke D. A., Tseng M. T., Miller F. N. A comparison of the effects of photodynamic therapy on normal and tumor blood vessels in the rat microcirculation. Radiat Res. 1989 Sep;119(3):542–552. [PubMed] [Google Scholar]
- Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
- Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
- Sasaki A., Jain R. K., Maghazachi A. A., Goldfarb R. H., Herberman R. B. Low deformability of lymphokine-activated killer cells as a possible determinant of in vivo distribution. Cancer Res. 1989 Jul 15;49(14):3742–3746. [PubMed] [Google Scholar]
- Sasaki A., Melder R. J., Whiteside T. L., Herberman R. B., Jain R. K. Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J Natl Cancer Inst. 1991 Mar 20;83(6):433–437. doi: 10.1093/jnci/83.6.433. [DOI] [PubMed] [Google Scholar]
- Schwarz R. E., Vujanovic N. L., Hiserodt J. C. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Cancer Res. 1989 Mar 15;49(6):1441–1446. [PubMed] [Google Scholar]
- Wiltrout R. H., Gorelik E., Brunda M. J., Holden H. T., Herberman R. B. Assessment of in vivo natural antitumor resistance and lymphocyte. Migration in mice: comparison of 125I-iododeoxyuridine with 111indium-oxine and 51chromium as cell labels. Cancer Immunol Immunother. 1983;14(3):172–179. doi: 10.1007/BF00205356. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wu N. Z., Klitzman B., Dodge R., Dewhirst M. W. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res. 1992 Aug 1;52(15):4265–4268. [PubMed] [Google Scholar]
